Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellSTU:MEB -1.48%77 Altman Z-Score is 5.75 as of Jul. 14, 2026, which is 1497% above its 10-year median of 0.36. GuruFocus rates STU:MEB with a GF Score™ of 77/100 and a GF Value™ of €22.08 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 928 Biotechnology companies, Medincell ranks better than 66.49% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 5.8 is strong.
Medincell has a Altman Z-Score of 5.75, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Medincell's Altman Z-Score or its related term are showing as below:
STU:MEB'
s Altman Z-Score Range Over the Past 10 Years
Min: -3.8 Med: 0.36 Max: 5.8
Current: 5.8
During the past 11 years, Medincell's highest Altman Z-Score was 5.80. The lowest was -3.80. And the median was 0.36.
Medincell (STU:MEB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Medincell Altman Z-Score Related Terms
Medincell Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Medincell's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MEB vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Medincell's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Medincell's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Medincell's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7036
+
1.4
*
0
+
3.3
*
-0.2392
+
0.6
*
9.1938
+
1.0
*
0.1806
=
5.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Medincell (STU:MEB) has a Altman Z-Score of 5.75 as of Jul. 14, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medincell and its competitors. This is 1497% above median its historical median of 0.36. According to the industry distribution chart, Medincell ranks #311 out of 928 companies in the Biotechnology industry, placing it in the top 33.5%.
Is Medincell's Altman Z-Score too high?
Medincell's current Altman Z-Score of 5.75 is 1497% above median its 10-year median of 0.36. The Biotechnology industry median Altman Z-Score is 2.69. Medincell's value of 5.75 is 113.8% above this industry median. Based on the distribution chart, Medincell ranks #311 out of 928 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medincell's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #311 out of 928 companies for Altman Z-Score. This puts Medincell in the upper half of its industry. The industry median Altman Z-Score is 2.69. Medincell's value of 5.75 is 113.8% above this benchmark. While the company's 10-year median is 0.36 vs. the industry median of 2.69, Medincell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.69, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Altman Z-Score of 5.75 is 113.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Altman Z-Score is 5.75, which is 1497% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Based on GuruFocus' analysis, Medincell (STU:MEB) is currently considered Modestly Overvalued. The stock's GF Value™ is €22.08, compared to a current price of €26.54 — trading 20.2% above its estimated fair value. The current Altman Z-Score is 5.75, which is 1497% above median its 10-year median of 0.36 and 113.8% above the Biotechnology industry median of 2.69. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Medincell (STU:MEB), the current Altman Z-Score is 5.75 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (STU:MEB) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of €26.54 is trading 20.2% above its estimated GF Value™ of €22.08.
GuruFocus considers Medincell to be Modestly Overvalued.
Key valuation signals for STU:MEB:
Altman Z-Score: 5.75 (1497% above median its 10-year median of 0.36)
GF Value™: €22.08 vs. price of €26.54 (20.2% above fair value)
Industry Position: 113.8% above the Biotechnology median (#311 of 928)
No single metric tells the full story. See the STU:MEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for STU:MEB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MEB has been successfully added to your 
